{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma%2C+Refractory&page=2", "query": { "condition": "Multiple Myeloma, Refractory", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma%2C+Refractory&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T09:30:09.666Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00726830", "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "methadone hydrochloride", "type": "DRUG" }, { "name": "morphine sulfate", "type": "DRUG" }, { "name": "oxycodone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2009-03", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 2, "location_summary": "Spartanburg, South Carolina • Houston, Texas", "locations": [ { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726830" }, { "nct_id": "NCT04136756", "title": "NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin Lymphoma", "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "NKTR-255", "type": "DRUG" }, { "name": "NKTR-255 Q21", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2019-10-07", "completion_date": "2023-04-24", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Duarte, California • San Francisco, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04136756" }, { "nct_id": "NCT01695330", "title": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Subcutaneous bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-05", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01695330" }, { "nct_id": "NCT00003195", "title": "Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "1997-12", "completion_date": "2000-11", "has_results": false, "last_update_posted_date": "2011-11-17", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003195" }, { "nct_id": "NCT02294357", "title": "Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-12", "completion_date": "2020-09-22", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 7, "location_summary": "Encinitas, California • West Hills, California • West Hollywood, California + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Poughkeepsie", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294357" }, { "nct_id": "NCT00079222", "title": "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "itraconazole", "type": "DRUG" }, { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079222" }, { "nct_id": "NCT05590377", "title": "A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Modakafusp Alfa", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-23", "completion_date": "2024-05-22", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 13, "location_summary": "Gilbert, Arizona • Los Angeles, California • Fort Wayne, Indiana + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05590377" }, { "nct_id": "NCT01592370", "title": "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lirilumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2012-08-02", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 32, "location_summary": "Clovis, California • Los Angeles, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01592370" }, { "nct_id": "NCT01330173", "title": "Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330173" }, { "nct_id": "NCT05182073", "title": "FT576 in Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma" ], "interventions": [ { "name": "FT576 (Allogenic CAR NK cells with BCMA expression)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-11-10", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-06-26T09:30:09.666Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05182073" } ] }